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OBJECTIVE—The objectives of the study were to determine
whether the cell cycle transcription factor, FoxM1, is required for
glucose homeostasis and -cell mass expansion in maternal islets
during pregnancy and whether FoxM1 is essential for placental
lactogen (PL)-induced -cell proliferation.
RESEARCH DESIGN AND METHODS—-Cell mass, -cell
proliferation, and glucose homeostasis were assessed in virgin,
pregnant, and postpartum mice with a pancreas-wide Foxm1
deletion (FoxM1
panc). Wild-type islets were cultured with or
without PL and examined for Foxm1 induction. Transgenic mice
overexpressing PL in -cells were bred with FoxM1
panc mice,
and -cell proliferation was examined.
RESULTS—Foxm1 was upregulated in maternal islets during
pregnancy. In contrast to controls, -cell proliferation did not
increase in pregnant FoxM1
panc females. Mutant islets showed
increased Menin and nuclear p27. FoxM1
panc females developed
gestational diabetes mellitus as pregnancy progressed. After
parturition, euglycemia was restored in FoxM1
panc females, but
islet size was signiﬁcantly reduced. Strikingly, -cell mass was
normal in postpartum FoxM1
panc pancreata due to a combina-
tion of increased -cell size and islet neogenesis. Evidence for
neogenesis included increased number of endocrine clusters,
increased proportion of smaller islets, and increased neurogenin
3 or insulin expression in cells adjacent to ducts. PL induced
Foxm1 expression in cultured islets, and FoxM1 was essential
for PL-mediated increases in -cell proliferation in vivo.
CONCLUSIONS—FoxM1 is essential for -cell compensation
during pregnancy. In the absence of increased -cell prolifera-
tion, neogenesis is induced in postpartum FoxM1
panc pancreata.
Our results suggest that FoxM1 functions downstream of PL to
mediate its effects on -cell proliferation. Diabetes 59:143–152,
2010
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estational diabetes mellitus (GDM) occurs in
3–7% of pregnancies (1,2). GDM onset typically
occurs in the second trimester due to increased
insulin resistance and inadequate -cell com-
pensation, similar to type 2 diabetes. GDM increases the
risk of type 2 diabetes later in life, and increases risk for
pregnancy complications such as preeclampsia and cesar-
ean sections. Infants born to mothers with GDM are at
higher risk for macrosomia. Postnatally, these infants are
at risk of developing hypoglycemia, hypocalcemia, polycy-
themia, jaundice, and respiratory distress syndrome (2,3).
Individuals born to mothers with GDM have higher risk of
obesity and type 2 diabetes as adults (2). GDM has a strong
genetic component, clustering in families and particular
minority ethnic groups; common variants in several genes
(KCNJ11, GK, and HNF4a) increase the risk of GDM
(2,4,5). -Cell mass adapts to physiological needs and
increased functional demands (6–8). Changes in -cell
mass can be achieved by hyperplasia (increased cell
number), hypertrophy (increased cell size), and neogene-
sis from progenitors. Pathways involved in maintaining or
augmenting -cell mass may be affected in diabetic indi-
viduals. This concept is reinforced by the recent ﬁnding
that polymorphisms in genes that regulate proliferation,
such as TCF7L2 and CDKN2, are linked with type 2
diabetes in humans (9,10). Although adult pancreatic ducts
retain the ability to generate new endocrine cells in
response to certain stimuli (11,12), most new adult -cells
arise from preexisting -cells (13,14).
During pregnancy, maternal insulin demands increase
due to the insulin resistance related to weight gain and
placental hormone production, increased fetal burden, and
increased food intake (7,15). Maternal islets adapt to this
increased demand mainly through enhanced insulin secre-
tion per -cell and increased -cell proliferation (15).
-Cell mass expands by 50% during pregnancy. The main
stimuli of -cell proliferation during pregnancy are placen-
tal lactogens (PLs), although prolactin (Prl) and growth
hormone (GH) have similar effects on -cells and are also
elevated during pregnancy (6,15,16). Transgenic mice ex-
pressing PL within -cells (RIP-mPL) exhibit increased
-cell proliferation and a doubling of -cell mass (17).
Very little is known about the molecular effectors that
act downstream of lactogenic hormones to regulate -cell
proliferation. Lactogens repress expression of the tran-
scriptional coactivator, Menin (18,19), and transgenic
overexpression of Menin in -cells resulted in GDM due to
decreased maternal -cell proliferation. Menin target
genes include p18 and p27, both cell cycle inhibitors
(18,19). These studies provide a link between a known
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“brake.” Whether PL or other pregnancy hormones acti-
vate cell cycle “accelerators” in -cells is currently un-
known. A thorough understanding of molecular regulators
of -cell mass may lead to strategies for enhancing -cell
proliferation in individuals prone to GDM and type 2
diabetes.
The FoxM1 transcription factor is highly expressed in
proliferating cells (20). FoxM1 directly activates genes
involved in DNA synthesis, karyokinesis, and cytokinesis,
including Cdc25A, Cdc25B, cyclin B1 (21–23), CENP-F
(24), polo-like kinase 1 (Plk-1), and Aurora B kinase (25).
FoxM1 target genes (Skp2, Cks1, KIS) also prevent nu-
clear localization of the Cdk inhibitor and Menin target
gene, p27
kip1 (26,27). FoxM1 is highly expressed in embry-
onic and neonatal pancreatic endocrine cells, but expres-
sion decreases as animals age (28). We previously showed
that FoxM1 regulates postnatal -cell proliferation and
-cell mass. Male mice lacking FoxM1 in their entire
pancreas (FoxM1
panc) displayed a 75% reduction in -cell
mass at 9 weeks and were overtly diabetic (28).
FoxM1
panc female mice maintained glucose homeostasis,
despite a similar decrease in -cell mass (12,28). We
predicted that decreased FoxM1 activity could result in an
inability to expand -cell mass during times of increased
metabolic demand. Consistent with this idea, we recently
reported that FoxM1
panc females have decreased -cell
regeneration and impaired -cell replication after partial
pancreatectomy (PPx) (12).
FoxM1 activity is also required for liver regeneration in
response to GH (29). We therefore hypothesized that
FoxM1 would be required for the hormone-induced in-
crease in -cell replication during pregnancy. In the cur-
rent study, FoxM1
panc females were used to examine the
role of FoxM1 in -cell mass expansion and maintenance
of glucose homeostasis during pregnancy. Foxm1 expres-
sion was upregulated in maternal islets during pregnancy,
and pregnant FoxM1
panc females showed decreased
-cell mass compared with controls. -Cell replication
failed to increase in mutant mice during pregnancy, result-
ing in overt GDM. Thus, FoxM1 plays a critical role in
-cell adaptation to pregnancy. Interestingly, islets from
FoxM1
panc females showed sustained defects after partu-
rition including decreased average islet size. However,
-cell mass was restored to normal in postpartum
FoxM1
panc females, likely due to stimulation of islet
neogenesis. In isolated islets, PL treatment induced
Foxm1 expression, suggesting that FoxM1 acts down-
stream of PL and may mediate its effects on -cell mass
regulation. Strongly supporting this hypothesis, we show
that inactivation of Foxm1 in pancreata of RIP-mPL trans-
genic mice completely prevents PL-mediated induction of
-cell proliferation.
RESEARCH DESIGN AND METHODS
Mice. Foxm1
ﬂ/ﬂ and FoxM1
panc mice and genotyping are described else-
where (23,25,28). RIP-mPL transgenic mice were as previously described (17).
All studies were performed with the approval of and in compliance with the
Vanderbilt Institutional Animal Care and Use Committee.
Tissue preparation and histology. Pancreata were ﬁxed in 4% paraformal-
dehyde at 4°C for 4 h. Tissues were dehydrated, embedded in parafﬁn, and
sectioned at 5 m. Primary antibodies used are as follows: guinea pig
anti-bovine insulin (Linco), 1:1,000; rat anti-bromodeoxyuridine (BrdU; Accu-
rate Chemical & Scientiﬁc), 1:400; rabbit anti-Glut2 (Alpha Diagnostic), 1:500;
mouse anti-Kip1/p27 (BD Biosciences), 1:100; mouse anti-neurogenin 3
(NGN3; Developmental Studies Hybridoma Bank), 1:100; and rabbit anti-
cytokeratin (Dako), 1:1,000. Incubations were overnight in a humid chamber
at 4°C. For BrdU detection, slides were treated with 1.5 N HCl for 20 min at
37°C, neutralized in sodium borate buffer for 1 min at room temperature, and
treated with 0.005 mg/ml trypsin (Sigma-Aldrich) and 0.005 mg/ml CaCl2 (in
Tris buffer; pH 7.5) for 3 min at 37°C. Vectastain ABC kit (Vector Labs) was
used for immunohistochemical labeling of insulin for -cell mass measure-
ment. The Histomouse-SP kit (Invitrogen) was used for detection of p27.
NGN3 and cytokeratin immunolabeling was performed as previously de-
scribed (12). Donkey anti-guinea pig cyanin 2 (Cy2) and donkey anti-rat Cy3
were used as secondary antibodies at a 1:500 dilution. Mounting medium
contained 1.5 g/ml nuclear ﬂuorogen DAPI (Molecular Probes).
Samples were viewed under bright-ﬁeld illumination or appropriate optical
ﬁlters (immunoﬂuorescence) using an Olympus BX41 microscope (Tokyo,
Japan) and digital camera with the Magnaﬁre program (Optronics). Tagged
image ﬁle format (TIFF) images from each experiment were processed
equivalently in Adobe Photoshop.
-Cell mass. Entire pancreata were removed, weighed, and ﬁxed as above.
Five-micron longitudinal sections were prepared for insulin immunoperoxi-
dase labeling and eosin counterstaining. Every 30th section (an average of
8–13 sections per pancreas) was used. Images of anti-insulin–labeled sections
were scanned using a Nikon Super CoolScan 9000. Using Metamorph 6.1
software (Molecular Devices), -cell mass was measured by obtaining the
fraction of cross-sectional area of pancreatic tissue positive for insulin and
multiplying this by the pancreatic weight (n  3 animals of each genotype at
each stage).
-Cell replication. BrdU (100 mg/kg; Sigma-Aldrich) was injected intraperi-
toneally every 2 h three times prior to pancreas tissue processing. BrdU-
labeled -cells were detected by double immunolabeling with insulin
antibodies and DAPI to visualize nuclei. Using Metamorph, BrdU-positive and
-negative nuclei in insulin-positive cells were counted at 400 magniﬁcation.
At least 3,000 -cells were counted for each of three animals of each genotype
at each stage. The proportion of BrdU-positive -cell nuclei to total -cell
nuclei was calculated and represents the percentage of -cells that have
recently gone through S-phase.
-Cell size. Pancreas sections were colabeled for Glut2 and insulin as
described above. Every islet from one section on each slide was photo-
graphed. Using Metamorph, the area of more than 1,000 individual -cells was
determined per mouse.
Total pancreatic and plasma insulin content. Dissected pancreata were
rinsed in PBS, blotted with ﬁlter paper, weighed, and homogenized (Polytron
PT 10/35; Brinkmann Instruments) in 1 ml of acid alcohol. The homogenate
was extracted with an additional 5 ml of acid alcohol for 48 h at 4°C and
centrifuged at 2,500 rpm for 30 min. Supernatants were assayed for insulin by
radioimmunoassay (30). Insulin concentrations were normalized to pancreas
wet weight.
For plasma insulin content, blood samples were collected at 0 and 30 min
after glucose injection during an intraperitoneal glucose tolerance test
(IPGTT) from the saphenous vein. The plasma supernatant was analyzed using
the Ultrasensitive ELISA kit (Alpco).
IPGTT. IPGTTs were performed on Foxm1
ﬂ/ﬂ and FoxM1
panc virgin females
and at gestational day (GD) 12.5 and GD15.5 as described (28). Controls for
these studies were Foxm1
ﬂ/ﬂ mice.
Islet RNA isolation and quantitative real-time RT-PCR. Islets were
isolated from virgin, GD14.5, and postpartum day 8 (P8) females by intraductal
collagenase perfusion. At least three mice were used per group. Total islet
RNA (75–125 islets/mouse) was extracted using the RNAqueous kit (Ambion).
RNA concentration and integrity were assessed using the ND-1000 Spectro-
photometer (NanoDrop) and the 2100 Electrophoresis Bioanalyzer (Agilent).
cDNA was synthesized using the Superscript III First-Strand synthesis
system (Invitrogen). Reactions were carried out in duplicate with iQ SYBR
Green supermix (Bio-Rad) at an annealing temperature of 58°C. Data were
collected using an iCycler iQ Real-Time PCR Detection System (Bio-Rad) and
software (Bio-Rad). Primers optimized by melting curve analysis were gener-
ated as follows: Foxm1 (forward, cacttggattgagaccactt; reverse, gtcgtttctgct-
gtgattcc), Bcl-xl (forward, ccttggatccaggagaacg; reverse, caggaaccagcggttgaa),
and hypoxanthine-guanine phosphoribosyltransferase (Hprt) (forward, agt-
caacgggggacataaaa; reverse, tgcattgttttaccagtgtcaa). Expression levels were
normalized against the levels of Hprt, a ubiquitously expressed gene that
shows little change during cellular growth or differentiation. Results were
analyzed using the 2
Ct method (31).
Western blotting. Islets from 8- to 12-week-old virgin and GD15.5 Foxm1
ﬂ/ﬂ
and FoxM1
panc females were lysed and sonicated with a Virsonic 100
sonicator (Virtis Company). The supernatant was quantiﬁed using the Bio-Rad
DC protein assay (Bio-Rad). Western blotting was done as previously de-
scribed using 10 g islet protein/lane from one animal (32). Membranes were
probed with primary antibodies diluted in 3% nonfat milk in Tris-buffered
saline (TBS) overnight at 4°C: goat anti-Menin (Bethyl Laboratories) 1:1,000;
rabbit anti-Pdx1 (a gift from Dr. Chris Wright, Vanderbilt University), 1:10,000;
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Biotechnology), 1:10,000. Peroxidase-conjugated species-speciﬁc secondary
antibodies (Jackson ImmunoResearch Laboratories) were diluted to 1:5,000 in
3% nonfat milk in TBS and incubated for1ha troom temperature. Protein
levels in individual lanes were quantiﬁed using ImageJ 1.42 (National Insti-
tutes of Health [NIH]) and normalized to the level of -actin signal in
corresponding lanes. Three to ﬁve animals per group were analyzed.
In vitro islet culture. Islets from 8- to 12-week-old Foxm1
ﬂ/ﬂ virgin females
were cultured for 4 days in 1 RPMI 1640 supplemented with 10% horse
serum, 11 mmol/l glucose, 100 units/ml penicillin, and 100 g/ml streptomycin
with or without 500 ng/ml human PL (National Hormone and Peptide
Program). An average of 50–60 islets were plated in one 60  15-mm
non–tissue culture–treated Petri dish at 37°C in 5% CO2. Cultures were
replenished with fresh medium with or without PL after 48-h incubation. After
4 days, RNA was extracted and subjected to quantitative (q)RT-PCR analysis.
-Cell apoptosis. Transferase-mediated dUTP nick-end labeling was per-
formed on parafﬁn sections of adult pancreata using the In Situ Cell Death
Detection kit (Roche) and followed by immunoﬂuorescent staining of insulin.
Cleaved caspase-3 was detected using an antibody raised in rabbit (Cell
Signaling Technology) at a dilution of 1:1,500. Immunoreactivity was detected
using the Vectastain ABC and DAB kits (Vector Labs).
Statistical analysis. Data were analyzed by Student t test or two-way
ANOVA with Bonferroni post-tests, using GraphPad Prism V5.01. A value of
P  0.05 was considered signiﬁcant.
RESULTS
Foxm1 expression is increased in islets during preg-
nancy. In pregnant mice, maternal -cell replication peaks
at GD14.5 (18) (supplementary Fig. 1, which is available in
the online appendix at http://diabetes.diabetesjournals.
org/cgi/content/full/db09-0050/DC1). -Cell mass expan-
sion during pregnancy is due mainly to stimulation of
proliferation by elevated circulating pregnancy hormones,
including, GH, Prl, and PL (6,15,16), as well as via cell
hypertrophy (8,33). We previously showed that FoxM1 is
required for postnatal -cell mass expansion and prolifer-
ation and is also necessary for -cell mass regeneration
after PPx (12,28). In the liver, FoxM1 activity is required
for GH-mediated stimulation of liver regeneration (29).
Thus, we hypothesized that FoxM1 would be required for
the hormone-induced increases in -cell proliferation and
-cell mass during pregnancy.
Antibodies that speciﬁcally recognize FoxM1 in mouse
tissue are not available. Thus, we examined whether
Foxm1 mRNA expression in maternal islets correlated
with -cell proliferation during pregnancy. Based on the
maternal -cell proliferation proﬁle during pregnancy,
qRT-PCR analysis was performed on isolated control islets
at virgin, GD14.5, and P8 stages. Maternal Foxm1 expres-
sion in control islets was elevated more than 50% at
GD14.5 and returned back to prepregnancy levels at P8
(Fig. 1). Thus, Foxm1 expression correlated with the
dynamics of -cell proliferation during pregnancy.
Impaired -cell mass expansion in pregnant
FoxM1
panc mice. We predicted that lack of FoxM1
would lead to decreased -cell proliferation and mass
during pregnancy. Signiﬁcantly fewer proliferating -cells
were observed in FoxM1
panc females compared with
controls (Fig. 2) at all stages. Controls displayed an
approximately threefold increase in -cell proliferation at
GD15.5, with no corresponding increase in FoxM1
panc
mice, clearly indicating that FoxM1 is important for in-
creased maternal -cell proliferation during pregnancy.
Our previous studies revealed an increase in nuclear p27
in neonatal islets in the absence of FoxM1 (28). Examina-
tion of islets from virgin and pregnant females revealed a
decrease in intensity of nuclear p27 expression in control
islets at GD15.5 (Fig. 3A and B). In contrast, islets from
virgin and GD15.5 FoxM1
panc females showed increased
nuclear p27 compared with control females (Fig. 3C and
D). There was no change in total p27 protein as detected
by Western blotting (data not shown). In addition, we
examined expression of Menin in control and FoxM1
panc
islets at virgin and GD15.5 stages. Islets from pregnant
control animals showed a decrease in Menin expression
compared with virgin mice, consistent with published
results (18). However, in FoxM1
panc islets from pregnant
females, Menin protein levels remained elevated (Fig. 3E).
The decrease in -cell proliferation observed in
FoxM1
panc females translated into decreased -cell mass.
Virgin FoxM1
panc females had a signiﬁcant decrease in
-cell mass compared with controls (Fig. 4A), although we
did not detect a signiﬁcant difference in total pancreatic
insulin content at baseline (Fig. 4B). A dramatic decrease in
-cell mass in FoxM1
panc females was also observed at
GD15.5 (Fig. 4A). Pregnancy neither stimulated -cell mass
expansion nor increased total pancreatic insulin content in
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FIG. 1. Foxm1 expression is increased during pregnancy. Quantitative
real-time RT-PCR was performed on isolated islets from 8- to 12-week-
old virgin (f), GD14.5 (), and P8 Foxm1
ﬂ/ﬂ females (p). The relative
expression units at GD14.5 and P8 were normalized to that of virgin
mice. A 1.7-fold increase in Foxm1 mRNA was observed in islets from
GD14.5 females compared with islets from virgin females. Unpaired t
tests were used to measure signiﬁcance. n  3–6 per group. Error bars
represent SD. **P < 0.01.
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FIG. 2. Decreased -cell proliferation in FoxM1
panc female mice.
Foxm1
ﬂ/ﬂ mice (f) showed a signiﬁcant increase in -cell proliferation
at midgestation compared with before pregnancy. FoxM1
panc females
() showed much lower -cell proliferation than control mice at every
time point, with no increase in -cell proliferation during pregnancy in
mutant mice. Two-way ANOVA with Bonferroni post-tests and two-
tailed Student t test were used to measure signiﬁcance. n  3–4 per
group. Error bars represent SD. *P < 0.05, **P < 0.01.
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panc females compared with virgin females (Fig. 4A
and B).
To determine whether loss of FoxM1 might also affect
-cell differentiation, we examined Pdx1 expression by
immunolabeling and Western blotting. Pdx1 expression
was unchanged in FoxM1
panc islets from either virgin or
pregnant females compared with controls (data not
shown). Sections from virgin and pregnant mice control
and FoxM1
panc pancreata were also examined for insulin
expression. Islets from control animals showed uniform
insulin reactivity (Fig. 4C and data not shown). In contrast,
although insulin expression in virgin FoxM1
panc islets
resembled controls, many cells labeled weakly in islets
from female FoxM1
panc at GD15.5 (Fig. 4D and E). These
low-level insulin-expressing cells were not undergoing
apoptosis, as there was no increase in apoptotic -cells in
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FIG. 3. Increased nuclear p27 in islets of GD15.5 FoxM1
panc females. p27 (brown) was detected in some islet nuclei in virgin control and
FoxM1
panc pancreata at 8–12 weeks of age (A and C). The number of nuclei strongly positive for p27 decreased in control pregnant females at
GD15.5 (B) compared with virgin controls (A). In both virgin and GD15.5 FoxM1
panc islets (C and D), nuclear localization of p27 was increased
compared with control islets at GD15.5 (B). The larger nuclei in FoxM1
panc pancreata are due to the endoreduplication known to occur in the
absence of Foxm1 (21). Representative images are shown (n  3 animals per group). Magniﬁcation 400. E: Quantiﬁcation of Western blotted
Menin protein from isolated islets. Menin protein decreases in control islets during pregnancy, but remains elevated in FoxM1
panc islets. n  3–4
animals per group. *P < 0.05. (A high-quality color digital representation of this ﬁgure is available in the online issue.)
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panc females (data not shown). Thus, loss
of FoxM1 results in both a decrease in the number of
proliferating maternal -cells during pregnancy as well
as a decrease in insulin expression in individual -cells.
Overall, these data suggest that FoxM1 is a key factor
promoting maternal -cell compensation during pregnancy.
Development of GDM in FoxM1
panc pregnant fe-
males. Virgin FoxM1
panc female mice remain euglycemic
(12,28) despite defects in -cell mass. Thus, IPGTT was
performed on 8- to 12-week-old virgin and pregnant fe-
males at GD12.5 and GD15.5 to determine whether preg-
nant female FoxM1
panc mice could maintain glucose
homeostasis despite defects in -cell proliferation and
-cell mass expansion. FoxM1
panc pregnant females
showed no dramatic differences in fasting blood glucose
levels compared with control females at either time point
examined. However, mutant females displayed impaired glu-
cose tolerance at GD12.5 (Fig. 5A) and overt GDM at GD15.5
(Fig. 5B). In humans, GDM is diagnosed if patients fail two or
more values on the 100-g glucose tolerance test. The normal
cutoff values are below 95 mg/dl at fasting, 180 mg/dl at 1 h,
155 mg/dl at 2 h, and 140 mg/dl at 3 h (2). An elevated fasting
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FIG. 4. Decreased -cell mass in virgin and pregnant FoxM1
panc mice. A: Compared with controls (f), -cell mass was signiﬁcantly decreased in
virgin and GD15.5 FoxM1
panc females (; n  3–4 per group). B: Virgin Foxm1
panc females have total pancreatic insulin content similar to virgin
controls. Insulin content in FoxM1
panc females decreased slightly during pregnancy. Two-way ANOVA with Bonferroni post-tests was used to
measure signiﬁcance (n  4–7 per group). C: Islets from control female mice at GD15.5 showed uniform insulin immunoreactivity as did islets
from virgin FoxM1
panc females (D). E: Islets from female FoxM1
panc mice showed patchy insulin reactivity at GD15.5 with some insulin-
producing cells labeling more strongly than others (arrows). *P < 0.05, **P < 0.01, ***P < 0.001. Error bars represent SEM. ns, not signiﬁcant.
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FIG. 5. FoxM1
panc mice developed glucose intolerance at GD12.5 and GDM at GD15.5. IPGTTs were performed on Foxm1
ﬂ/ﬂ (F) and FoxM1
panc
(E) females at GD12.5 (A) and GD15.5 (B) after a 16-h fast. At GD12.5, FoxM1
panc females displayed impaired glucose tolerance at 90 and 120
min (A). FoxM1
panc females progressed to GDM by GD15.5 (B). Two-way ANOVA with Bonferroni post-test was used to measure signiﬁcance of
difference. n  5–10 per group. Error bars represent SEM. *P < 0.05.
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of GDM (2). One hour after glucose challenge, blood glucose
levels in FoxM1
panc females were greater than 300 mg/dl. In
addition, the blood glucose concentration 2 h after glucose
challenge was 200 mg/dl (Fig. 5B). The mean plasma
insulin level in control mice at GD15.5 was 231.7 pg/ml at
fasting and 977.2 pg/ml at 30 min (n  2). In contrast, mean
plasma insulin level in FoxM1
panc females was 304.6 pg/ml
at fasting and 361.3 pg/ml at 30 min (n  4). These results
demonstrate that FoxM1 is absolutely essential for the main-
tenance of glucose homeostasis during pregnancy and that
loss of FoxM1 results in a reduced capacity for -cell
compensation in the face of increasing insulin resistance as
pregnancy proceeds.
Loss of Foxm1 results in sustained islet defects after
parturition. Because prior GDM elevates the risk for type 2
diabetes later in life, we examined whether there were
any deleterious lasting consequences of pregnancy in
FoxM1
panc females. Eight days after giving birth,
FoxM1
panc females tended to have higher blood glucose
levels during an IPGTT than postpartum control females;
however, these did not reach statistical signiﬁcance (supple-
mentary Fig. 2). The impaired -cell proliferation observed in
FoxM1
panc virgin females was still observed at P8 (Figs. 2
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FIG. 6. Lasting postpartum changes in FoxM1
panc female pancreata. BrdU incorporation (red) was used to assess active -cell proliferation
(insulin [Ins]: green) in maternal islets at P8. Control islets (A) were larger and showed increased BrdU incorporation compared with FoxM1
panc
islets (B; see also Fig. 2). C: The proportion of small islet clusters (1–8 cells) was signiﬁcantly increased in FoxM1
panc pancreata at P8 compared
with controls (n  3; P < 0.05). Rare NGN3-positive cells (green) were observed adjacent to ducts (cytokeratin: red) at P2 (not shown) and P4
(D). Juxtaductal insulin-positive cells were observed in FoxM1
panc pancreata at P8 (arrow in E). Magniﬁcation 400. (A high-quality color
digital representation of this ﬁgure is available in the online issue.)
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panc pancreata
were smaller than those in controls (Figs. 6A and B and 7A).
Sections from P8 control islets contained an average of 21
-cells per islet, whereas sections from P8 FoxM1
panc
islets contained an average of only 9 -cells per islet. After
parturition, FoxM1
panc females exhibited a signiﬁcant
increase in the proportion of small endocrine cell clusters
(1–8 cells) versus deﬁnitive islets (8 cells) in comparison
with control mice (Fig. 6C), likely contributing to the
differences observed in average islet size (Fig. 7A). Al-
though it is possible that small endocrine clusters repre-
sent sections through the “top” of an islet of normal size,
we observe this increase in small islet clusters only in
postpartum FoxM1
panc females; no differences were ob-
served in the proportion of small endocrine cell clusters
between control and FoxM1
panc virgin females (12) (data
not shown).
Despite the decrease in islet size, total -cell mass was
normal in FoxM1
panc females after parturition (Fig. 7B
and C). This is likely due to a combination of increased
individual -cell size (Fig. 7E) and an increase in the actual
number of islet clusters in FoxM1
panc pancreata (Fig.
7D), possibly due to neogenesis. Postpartum FoxM1
panc
pancreata contained rare NGN3-expressing cells adjacent
to ducts at P2 and P4 and juxtaductal insulin-positive cells
at P8 (Fig. 6D and E). Thus, NGN3 expression preceded
insulin expression, suggestive of neogenesis. NGN3-
positive cells were not observed in control pancreata at
any time point examined (virgin, GD15.5, P2, P4, and P8)
or in FoxM1
panc pancreata from virgin, GD15.5, or P8
females.
FoxM1 is essential for PL-mediated increases in -cell
proliferation and -cell mass. PL is the primary lacto-
genic hormone that stimulates -cell proliferation during
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FIG. 7. Postpartum FoxM1
panc pancreata show normal -cell mass
due to increased number of islets. A: Average islet size was decreased
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in the number of insulin
 clusters (D) and increased average -cell
size (E) in FoxM1
panc pancreata compared with controls. n  3–4 per
group. *P < 0.05.
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downstream of PL to promote -cell proliferation during
pregnancy, Foxm1 expression was examined in isolated
Foxm1
ﬂ/ﬂ female islets exposed to PL in culture. As shown
in Fig. 8A, PL treatment increased expression of Bcl-xl,a
known target of PL signaling. In addition, Foxm1 expres-
sion was increased approximately threefold. As a more
direct test of whether FoxM1 functions downstream of PL,
RIP-mPL transgenic mice were interbred with FoxM1
panc
mice. RIP-mPL mice express PL under the control of the
rat insulin promoter and have a twofold increase in -cell
proliferation (17). FoxM1 was absolutely essential for the
PL-mediated increase in -cell proliferation in RIP-mPL
transgenic mice (Fig. 8B).
DISCUSSION
During pregnancy, -cell mass increases by 50% due to
stimulation of proliferation by GH, Prl, and most impor-
tantly, PL (6,15,16). Foxm1 expression strongly correlated
with the dynamics of maternal -cell proliferation during
pregnancy and was induced in response to PL in cultured
islets. In contrast to the partial requirement we recently
described for FoxM1 in -cell regeneration and prolifera-
tion after PPx (12), we found that FoxM1 is absolutely
essential for -cell mass expansion during pregnancy.
These data, combined with the fact that FoxM1 is neces-
sary for PL-induced -cell proliferation in RIP-mPL trans-
genic mice, point to FoxM1 as a downstream target of PL
signaling and an essential mediator of PL activity in islets.
Because pregnancy is a physiological stimulus of -cell
proliferation, understanding the molecular pathways in-
volved in pregnancy-induced -cell mass expansion could
facilitate identiﬁcation of therapeutic targets for enhanc-
ing -cell mass in vitro or in vivo.
Our data show that FoxM1 negatively regulates protein
levels of the cell cycle inhibitor, Menin. We do not yet know
whether this is at the level of transcription. However, the
effect of FoxM1 on p27 in our model is mainly at the level of
protein localization because total p27 levels were unchanged
in FoxM1
panc pancreata. FoxM1 promotes p27 nuclear ex-
port in other systems (27). Interestingly, Menin expression is
negatively regulated by lactogens (18). In the future, it will be
interesting to examine whether Stat5 directly regulates the
Foxm1 gene in -cells in response to PL and to determine the
mechanism whereby FoxM1 regulates Menin in conjunction
with pregnancy hormones.
In addition to enhancing -cell mass and -cell prolifer-
ation, PL and other pregnancy hormones enhance -cell
function. Functional changes in maternal -cells include a
lowered threshold for glucose-stimulated insulin secre-
tion, increased glucokinase activity, enhanced insulin
biosynthesis, increased gap junctional communication,
and increased islet blood ﬂow (6,34–37). Islets from
FoxM1
panc pregnant females showed reduced insulin
labeling per -cell and reduced total pancreatic insulin
content. Thus, -cell defects in the absence of FoxM1 may
not be limited to a dramatic decrease in -cell prolifera-
tion. Preliminary data from our laboratory suggest that
loss of FoxM1 impairs -cell function when animals are
exposed to a high-fat diet (A. Ackermann Misfeldt, U.G.
Kopsombut, and M.G., unpublished observations).
After parturition, a combination of decreased prolifera-
tion, increased apoptosis, and decreased cell size normally
restores -cell mass to prepregnancy levels within 10 days
(38). It was striking to us that 8 days after giving birth,
islets in FoxM1
panc pancreata were signiﬁcantly smaller
than those in controls, although glucose homeostasis and
-cell mass were restored. Our data strongly suggest that
in the absence of -cell proliferation, postpartum
FoxM1
panc pancreata generate new -cells via neogene-
sis, a process we previously showed does not require
FoxM1 in embryos or adults (12).
GDM results from an interaction between genetic and
environmental risk factors. Common variants in several
candidate genes increase the risk of GDM in humans (e.g.,
KCNJ11, GK, and HNF4a) (4); however, very few mouse
models of GDM currently exist. Heterozygous leptin recep-
tor–deﬁcient mice (db/	) spontaneously develop GDM
due to increased peripheral insulin resistance (39). In
addition, -cell–speciﬁc inactivation of HNF4
 resulted in
impaired glucose tolerance in virgin females that worsens
during pregnancy, although these animals do not manifest
deﬁnitive GDM (40). HNF4
 is required for increased
-cell proliferation and -cell mass during pregnancy (40).
Similarly, transgenic induction of Menin expression in
islets of pregnant females resulted in moderate hypergly-
cemia by GD9.0 that worsened as pregnancy progressed
(18); however, even the control females in this study
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GDM IN THE ABSENCE OF FoxM1
150 DIABETES, VOL. 59, JANUARY 2010 diabetes.diabetesjournals.orgshowed elevated blood glucose. The model presented here
is more similar to human GDM in that a phenotype is
manifested speciﬁcally at midgestation; virgin and P8
FoxM1
panc females show no overt phenotype. Human
GDM patients likely have an underlying undetected -cell
defect that becomes apparent only under the physiological
stress of pregnancy. Future studies will examine whether
prior GDM predisposes FoxM1
panc females to type 2
diabetes later in life, a phenotype that never manifests in
FoxM1
panc virgin females.
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